External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Inflammatory Disease Inflammatory Bowel Disease

Inflammatory Bowel Disease

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Feb 25 / Roche
New frontiers in inflammatory bowel disease TL1A inhibition – from mode of action to clinical application
This symposium discussed how the current unmet medical need in IBD needs and how anti-TL1A therapies have the potential to address that need highlighting data from recent trials and a overview of the proposed mechanism of action of TL1A.
Inflammatory Disease Inflammatory Bowel Disease ECCO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 22 / Roche and Genentech
Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis - Results from TUSCANY-2
Histologic and endoscopic improvement and remission data from the TUSCANY-2 trial. This was a randomised, double-blind, placebo-controlled, dose-ranging Phase IIb study of RO7790121, an antibody against tumour necrosis factor like ligand 1A (anti-TL1A) in adults with moderately to severely active ulcerative colitis.
Inflammatory Disease Inflammatory Bowel Disease ECCO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 21 / Roche and Genentech
RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active Ulcerative Colitis - Findings from the phase 2b TUSCANY-2 trial
Data from post-hoc analyses of patient-reported outcomes (PROs) from the TUSCANY-2 trial. This was a randomised, double-blind, placebo-controlled, dose-ranging Phase IIb study of RO7790121, an antibody against tumour necrosis factor like ligand 1A (anti-TL1A) in adults with moderately to severely active ulcerative colitis.
Inflammatory Disease Inflammatory Bowel Disease ECCO-2025
Upcoming congresses
Access to Roche and Genentech’s latest medical information

Sign up or login to unlock the full suite of MEDICALLY features
May 3 - May 6, 2025 / San Diego, USA / Virtual (Hybrid)
DDW 2025
Inflammatory Disease Inflammatory Bowel Disease
Subject:
Digestive Disease Week - 2025
Venue:
Medical Booth Number:
Notify me

Sign up or login to unlock the full suite of MEDICALLY features
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.